Article: article from journal or magazin.
Evidence for multiple B- and T-cell epitopes in Plasmodium falciparum liver-stage antigen 3.
Infection and immunity
Liver-stage antigen 3 (LSA-3) is a new vaccine candidate that can induce protection against Plasmodium falciparum sporozoite challenge. Using a series of long synthetic peptides (LSP) encompassing most of the 210-kDa LSA-3 protein, a study of the antigenicity of this protein was carried out in 203 inhabitants from the villages of Dielmo (n = 143) and Ndiop (n = 60) in Senegal (the level of malaria transmission differs in these two villages). Lymphocyte responses to each individual LSA-3 peptide were recorded, some at high prevalences (up to 43%). Antibodies were also detected to each of the 20 peptides, many at high prevalence (up to 84% of responders), and were directed to both nonrepeat and repeat regions. Immune responses to LSA-3 were detectable even in individuals of less than 5 years of age and increased with age and hence exposure to malaria, although they were not directly related to the level of malaria transmission. Thus, several valuable T- and B-cell epitopes were characterized all along the LSA-3 protein, supporting the antigenicity of this P. falciparum vaccine candidate. Finally, antibodies specific for peptide LSP10 located in a nonrepeat region of LSA-3 were found significantly associated with a lower risk of malaria attack over 1 year of daily clinical follow-up in children between the ages of 7 and 15 years, but not in older individuals.
Adolescent, Adult, Aged, Aged, 80 and over, Animals, Antibodies, Protozoan/blood, Antibodies, Protozoan/immunology, Antigens, Protozoan/immunology, Child, Child, Preschool, Epitopes, B-Lymphocyte/immunology, Epitopes, T-Lymphocyte/immunology, Humans, Malaria Vaccines/immunology, Malaria, Falciparum/immunology, Middle Aged, Peptides/immunology, Plasmodium falciparum/immunology, Senegal
Web of science
Last modification date